Cross Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications

Mol Cell Biol. 2016 May 31;36(12):1734-9. doi: 10.1128/MCB.00130-16. Print 2016 Jun 15.

Abstract

Aberrant activation of the Wnt/β-catenin pathway and polo-like kinase 1 (Plk1) overexpression represent two common events in prostate cancer with relevant functional implications. This minireview analyzes their potential therapeutic significance in prostate cancer based on their role as androgen receptor (AR) signaling regulators and the pivotal role of the tumor suppressor protein phosphatase 2A (PP2A) modulating these pathways.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Autoantigens / metabolism*
  • Cell Cycle Proteins / antagonists & inhibitors
  • Cell Cycle Proteins / metabolism*
  • Drug Resistance, Neoplasm / drug effects
  • Drug Therapy, Combination
  • Gene Expression Regulation, Neoplastic / drug effects
  • Humans
  • Intracellular Signaling Peptides and Proteins
  • Male
  • Membrane Proteins / antagonists & inhibitors
  • Membrane Proteins / metabolism*
  • Polo-Like Kinase 1
  • Prostatic Neoplasms / drug therapy
  • Prostatic Neoplasms / metabolism*
  • Protein Serine-Threonine Kinases / antagonists & inhibitors
  • Protein Serine-Threonine Kinases / metabolism*
  • Proto-Oncogene Proteins / antagonists & inhibitors
  • Proto-Oncogene Proteins / metabolism*
  • Up-Regulation / drug effects
  • Wnt Signaling Pathway* / drug effects

Substances

  • Antineoplastic Agents
  • Autoantigens
  • CIP2A protein, human
  • Cell Cycle Proteins
  • Intracellular Signaling Peptides and Proteins
  • Membrane Proteins
  • Proto-Oncogene Proteins
  • Protein Serine-Threonine Kinases